OPDP joins Amarin's Vascepa tale

Share this article:
OPDP joins Amarin's Vascepa tale
OPDP joins Amarin's Vascepa tale

Amarin's fish-oil drug Vascepa continued to take a beating as 2013 wrapped. Among the lowish lights in the company's pursuit of an indication that would allow a broader patient population to use the triglyceride-lowering medication: a 9-2 advisory panel vote against an expanded indication, and the FDA's decision to reject results from the ANCHOR study to support the expanded indication. The FDA's ability to backtrack on ANCHOR was within its rights, and the purpose was that the study would provide an immediate data pool while Amarin waited for other trial data to roll in.

The FDA then upset the generally linear order of things—panel review, regulator decision—Dec. 20 saying it was not going to rule on the drug which had a Dec. 29 PDUFA date. MKM Partners managing director John LeCroy told Reuters that was “a positive relative to Amarin getting a rejection.”

Adding to the tension—which Reuters noted had sapped the company's stock—was yet another negative: an untitled Dec. 16 letter in which the regulator calls out the drug maker for focusing so much on the drug's efficacy claims on a webcast series invitation that the risks associated with the drug did not make it onto the page, an omission the FDA writes “misleadingly suggests that Vascepa is safer than has been demonstrated.”

The regulator also noted that a printed direction to “see full prescribing information” was a solution it would not buy into because the instructions fail to “mitigate the misleading omission of risk information from the print invitation.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...